Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPIES FOR SOLID TUMOURS

(2014) M Van den Eynde et al.   ACTA CLINICA BELGICA

Antiangiogenic therapies in glioblastoma multiforme

(2012) Mairéad G McNamara et al.   Expert Review of Anticancer Therapy

Immunotherapy for Glioma

(2012) Seunggu J. Han et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

(2011) Greta Garrido et al.   CANCER BIOLOGY & THERAPY

Recent advancements in multimodality treatment of gliomas

(2011) Mersiha Hadziahmetovic et al.   Future Oncology

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

(2010) Marta Osorio Rodríguez et al.   CANCER BIOLOGY & THERAPY

Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis

(2010) S. Mazzoleni et al.   CANCER RESEARCH

Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

(2010) Maura Massimino et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

(2010) Benoit You et al.   INVESTIGATIONAL NEW DRUGS

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

(2010) Melarkode S. Ramakrishnan et al.   mAbs

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

(2009) B. Neyns et al.   ANNALS OF ONCOLOGY

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies

(2009) A Diaz Miqueli et al.   BRITISH JOURNAL OF CANCER

Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation

(2009) A. Talavera et al.   CANCER RESEARCH

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

(2009) William Kells Boland et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Nimotuzumab in pediatric glioma

(2009) Catherine Lam et al.   Future Oncology

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Oncogenic EGFR Signaling Networks in Glioma

(2009) P. H. Huang et al.   Science Signaling

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

(2008) A. A. Brandes et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

(2008) J. F. de Groot et al.   JOURNAL OF NEURO-ONCOLOGY

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

(2007) Fernando Rivera et al.   ACTA ONCOLOGICA

A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas

(2007) Amanda L. Schwer et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS